{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:25:08Z","timestamp":1788323108969,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016348","name":"Kyowa Kirin Pharmaceutical Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapy for patients with T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL), adult T-cell lymphoma (ATL), and peripheral T-cell lymphoma (PTCL). Mogamulizumab is an anti-CCR4 antibody that has been associated with an increased risk of transplant-related complications in retrospective analyses of ATL, particularly when administered within 50\u00a0days before transplantation. This post hoc analysis of 3 clinical trials examined safety and outcome data for 32 patients with CTCL (<jats:italic>n<\/jats:italic>\u2009=\u200923), ATL (<jats:italic>n<\/jats:italic>\u2009=\u20097), or PTCL (<jats:italic>n<\/jats:italic>\u2009=\u20092) who underwent allo-HSCT after mogamulizumab treatment. Overall, 22 patients (69%) were known to have graft-versus-host disease (GVHD), 8 patients (25%) did not report GVHD, and 2 patients (6%) had unknown GVHD status. Fourteen patients with known GVHD underwent transplantation between 50 and 365\u00a0days after their last dose of mogamulizumab, while 2 underwent transplantation within 50\u00a0days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.<\/jats:p>","DOI":"10.1007\/s12185-024-03753-9","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T03:01:55Z","timestamp":1711508515000},"page":"736-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis"],"prefix":"10.1007","volume":"119","author":[{"given":"Mary Jo","family":"Lechowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ristuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,27]]},"reference":[{"issue":"3","key":"3753_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3753_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medsci9010005","volume":"9","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci (Basel). 2021;9(1):5. https:\/\/doi.org\/10.3390\/medsci9010005.","journal-title":"Med Sci (Basel)"},{"issue":"6","key":"3753_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","volume":"11","author":"A Phan","year":"2016","unstructured":"Phan A, Veldman R, Lechowicz MJ. T-cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep. 2016;11(6):492\u2013503. https:\/\/doi.org\/10.1007\/s11899-016-0353-y.","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"3753_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2018-01-791335","volume":"132","author":"N Schmitz","year":"2018","unstructured":"Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132(3):245\u201353. https:\/\/doi.org\/10.1182\/blood-2018-01-791335.","journal-title":"Blood"},{"key":"3753_CR5","doi-asserted-by":"publisher","unstructured":"Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic hematopoietic stem cell transplantation in cutaneous T-cell lymphomas. Cancers (Basel). 2020;12(10):2856. https:\/\/doi.org\/10.3390\/cancers12102856.","DOI":"10.3390\/cancers12102856."},{"issue":"9","key":"3753_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3753_CR7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12885-021-08363-w","volume":"21","author":"T Zhang","year":"2021","unstructured":"Zhang T, Sun J, Li J, Zhao Y, Zhang T, Yang R, et al. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies. BMC Cancer. 2021;21(1):618. https:\/\/doi.org\/10.1186\/s12885-021-08363-w.","journal-title":"BMC Cancer"},{"key":"3753_CR8","unstructured":"POTELIGEO. Prescribing information. Kyowa Kirin, Inc; 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761051s015lbl.pdf. Accessed 28 June 2023."},{"issue":"28","key":"3753_CR9","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","volume":"34","author":"S Fuji","year":"2016","unstructured":"Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016;34(28):3426\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.67.8250.","journal-title":"J Clin Oncol"},{"key":"3753_CR10","doi-asserted-by":"publisher","unstructured":"Kamada Y, Arima N, Hayashida M, Nakamura D, Yoshimitsu M, Ishitsuka K. Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab. Leuk Lymphoma. 2022:1701\u20137. https:\/\/doi.org\/10.1080\/10428194.2022.2043300.","DOI":"10.1080\/10428194.2022.2043300."},{"issue":"1","key":"3753_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clml.2016.09.009","volume":"17","author":"S Iyama","year":"2017","unstructured":"Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, et al. A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia\/lymphoma. Clin Lymphoma Myeloma Leuk. 2017;17(1):23-30.e22. https:\/\/doi.org\/10.1016\/j.clml.2016.09.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"3753_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/bmt.2015.315","volume":"51","author":"Y Inoue","year":"2016","unstructured":"Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant. 2016;51(5):725\u20137. https:\/\/doi.org\/10.1038\/bmt.2015.315.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3753_CR13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","volume":"22","author":"T Sugio","year":"2016","unstructured":"Sugio T, Kato K, Aoki T, Ohta T, Saito N, Yoshida S, et al. Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22(9):1608\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2016.05.017.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"3753_CR14","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","volume":"101","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau MED, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma. Haematologica. 2016;101(10):e407\u201310. https:\/\/doi.org\/10.3324\/haematol.2016.146977.","journal-title":"Haematologica"},{"issue":"5","key":"3753_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3324\/haematol.2018.205096","volume":"104","author":"AA Phillips","year":"2019","unstructured":"Phillips AA, Fields PA, Hermine O, Ramos JC, Beltran BE, Pereira J, et al. Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma. Haematologica. 2019;104(5):993\u20131003. https:\/\/doi.org\/10.3324\/haematol.2018.205096.","journal-title":"Haematologica"},{"issue":"8","key":"3753_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837\u201342. https:\/\/doi.org\/10.1200\/JCO.2011.37.3472.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3753_CR17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.bbmt.2013.09.014","volume":"19","author":"T Ishida","year":"2013","unstructured":"Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, et al. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study. Biol Blood Marrow Transplant. 2013;19(12):1731\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2013.09.014.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"17","key":"3753_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.4103\/0366-6999.239315","volume":"131","author":"W-R Huang","year":"2018","unstructured":"Huang W-R, Liu D-H. Peripheral T-cell lymphomas: updates in allogeneic hematopoietic stem cell transplantation. Chin Med J (Engl). 2018;131(17):2105\u201311. https:\/\/doi.org\/10.4103\/0366-6999.239315.","journal-title":"Chin Med J (Engl)"},{"issue":"8","key":"3753_CR19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41409-022-01713-7","volume":"57","author":"D Angelov","year":"2022","unstructured":"Angelov D, Dillon J, Mellerick L, Pender E, Bacon L, Lee G, et al. Allogeneic transplantation in cutaneous T-cell lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease. Bone Marrow Transplant. 2022;57(8):1332\u20134. https:\/\/doi.org\/10.1038\/s41409-022-01713-7.","journal-title":"Bone Marrow Transplant"},{"issue":"29","key":"3753_CR20","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","volume":"28","author":"RF Duarte","year":"2010","unstructured":"Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492\u20139. https:\/\/doi.org\/10.1200\/JCO.2010.29.3241.","journal-title":"J Clin Oncol"},{"key":"3753_CR21","doi-asserted-by":"publisher","unstructured":"Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2021;56(6):1391\u2013401. https:\/\/doi.org\/10.1038\/s41409-020-01197-3.","DOI":"10.1038\/s41409-020-01197-3."},{"issue":"11","key":"3753_CR22","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/bmt.2014.161","volume":"49","author":"MJ Lechowicz","year":"2014","unstructured":"Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and S\u00e9zary syndrome. Bone Marrow Transplant. 2014;49(11):1360\u20135. https:\/\/doi.org\/10.1038\/bmt.2014.161.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"3753_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hon.2719","volume":"38","author":"T Mori","year":"2020","unstructured":"Mori T, Shiratori S, Suzumiya J, Kurokawa M, Shindo M, Naoyuki U, et al. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome. Hematol Oncol. 2020;38(3):266\u201371. https:\/\/doi.org\/10.1002\/hon.2719.","journal-title":"Hematol Oncol"},{"issue":"18","key":"3753_CR24","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1182\/bloodadvances.2020001627","volume":"4","author":"W-K Weng","year":"2020","unstructured":"Weng W-K, Arai S, Rezvani A, Johnston L, Lowsky R, Miklos D, et al. Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Adv. 2020;4(18):4474\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2020001627.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03753-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:03:01Z","timestamp":1716998581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03753-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,27]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3753"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03753-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,27]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>ML<\/b> reports consulting fees from Secura Bio, EUSA Pharma, and Kyowa Kirin, and travel support from Secura Bio. <b>CS<\/b>, <b>RR,<\/b> and <b>KD<\/b> are employees of Kyowa Kirin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}